{rfName}
No

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Mitjavila MAuthorSalas CAuthor

Share

June 15, 2019
Publications
>
Article
No

Noncirrhotic portal hypertension: An under-reported late adverse event of SIRT in metastatic colorectal cancer patients

Publicated to:Journal of Cancer Research and Therapeutics. 15 (1): 42-47 - 2019-01-01 15(1), DOI: 10.4103/jcrt.JCRT_1398_16

Authors: Gutierrez, Lourdes; Mendez, Santiago; Mitjavila, Mercedes; Llop, Elba; Salas, Clara; Ruiz-Casado, Ana

Affiliations

Hosp Univ Puerta Hierro Majadahonda, Dept Gastroenterol, Madrid, Spain - Author
Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Madrid, Spain - Author
Hosp Univ Puerta Hierro Majadahonda, Dept Nucl Med, Madrid, Spain - Author
Hosp Univ Puerta Hierro Majadahonda, Dept Pathol, Madrid, Spain - Author
Hosp Univ Puerta Hierro Majadahonda, Dept Vasc Radiol, Madrid, Spain - Author
Hospital Universitario Puerta de Hierro - Author
See more

Abstract

© 2019 Journal of Cancer Research and Therapeutics | Published by Wolters Kluwer - Medknow. Introduction: Selective internal radiation therapy (SIRT) is increasingly used in different scenarios. Although portal hypertension (PHT) has been described as a nonclinically relevant finding after SIRT, its real incidence could have been neglected due to the nature of the diseases for which SIRT is indicated. Case Reports: Here we report three cases with clinically relevant late PHT after treatments including SIRT and oxaliplatin among others. Discussion: The sequential use of oxaliplatin and SIRT in patients with colorectal cancer metastases could have additive effects on the liver.

Keywords

late toxicityliver metastasesmicrospheresmulticenterportal hypertensionradioembolizationradiotherapyregenerative nodular hyperplasiasafetysirtLate toxicityLiver metastasesOxaliplatin-based chemotherapyPortal hypertensionRegenerative nodular hyperplasiaSirt

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal of Cancer Research and Therapeutics due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2019, it was in position , thus managing to position itself as a Q2 (Segundo Cuartil), in the category Radiology, Nuclear Medicine and Imaging. Notably, the journal is positioned en el Cuartil Q4 for the agency WoS (JCR) in the category Oncology.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.7, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-18, the following number of citations:

  • WoS: 5
  • Scopus: 5
  • Europe PMC: 2

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-18:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 15 (PlumX).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.